NCT06531863 Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance
| NCT ID | NCT06531863 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Auburn University |
| Condition | Mood Disturbance |
| Study Type | INTERVENTIONAL |
| Enrollment | 64 participants |
| Start Date | 2024-09-30 |
| Primary Completion | 2025-05-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 64 participants in total. It began in 2024-09-30 with a primary completion date of 2025-05-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)
Eligibility Criteria
Inclusion Criteria: * Adults age 18-50 * Depression subscale score of \>9/21 on the DASS-21 * No change in medications or supplements over the past 3 months * Can read and speak English Exclusion Criteria: * Currently consume curcumin or green tea daily * Currently, pregnant, nursing, or trying to become pregnant * Currently diagnosed with a perimenopausal disorder
Contact & Investigator
Andrew D Fruge, PhD
PRINCIPAL INVESTIGATOR
Auburn University
Frequently Asked Questions
Who can join the NCT06531863 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Mood Disturbance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06531863 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06531863 currently recruiting?
Yes, NCT06531863 is actively recruiting participants. Contact the research team at amc0108@auburn.edu for enrollment information.
Where is the NCT06531863 trial being conducted?
This trial is being conducted at Auburn, United States.
Who is sponsoring the NCT06531863 clinical trial?
NCT06531863 is sponsored by Auburn University. The principal investigator is Andrew D Fruge, PhD at Auburn University. The trial plans to enroll 64 participants.